Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status

Neurobiology of Aging

Volumn 33, Issue 7, 2012, Pages 1265-1272

  Choi, Seo Hee ^a   Jung, Tae Min ^a   Lee, Ji E ^a   Lee, Seung Koo ^a   Sohn, Young H ^a   Lee, Phil Hyu ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Dementia; Mild cognitive impairment; Parkinson's disease; Substantia innominata

Indexed keywords

AGED; ARTICLE; ATTENTION; BRAIN ATROPHY; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DEMOGRAPHY; DISEASE DURATION; FEMALE; FOREBRAIN; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA INNOMINATA; VOLUMETRY;

AGED; COGNITION DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; ORGAN SIZE; PARKINSON DISEASE; PROSPECTIVE STUDIES; SUBSTANTIA INNOMINATA;

EID: 84861191579     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.11.015     Document Type: Article

References (34)

1. Aarsland D., Bronnick K., Larsen J.P., Tysnes O.B., Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009, 72:1121-1126.
2. Aarsland D., Larsen J.P., Reinvang I., Aasland A.M. Effects of cholinergic blockade on language in healthy young women. Implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain 1994, 117:1377-1384.
3. Amaducci L., Sorbi S., Albanese A., Gainotti G. Choline acetyltransferase (ChAT) activity differs in right and left human temporal lobes. Neurology 1981, 31:799-805.
4. Baxter M.G., Chiba A.A. Cognitive functions of the basal forebrain. Curr. Opin. Neurobiol 1999, 9:178-183.
5. Biggins C.A., Boyd J.L., Harrop F.M., Madeley P., Mindham R.H., Randall J.I., Spokes E.G. A controlled, longitudinal study of dementia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1992, 55:566-571.
6. Bohnen N.I., Albin R.L. The cholinergic system and Parkinson disease. Behav. Brain Res 2010, 10.1016/j.bbr.2009.12.048.
7. Bohnen N.I., Kaufer D.I., Hendrickson R., Ivanco L.S., Lopresti B.J., Constantine G.M.MathisChA., Davis J.G., Moore R.Y., Dekosky S.T. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J. Neurol 2006, 253:242-247.
8. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen-Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
9. Caballol N., Marti M.J., Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov. Disord 2007, 22:S358-S366.
10. Caviness J.N., Driver-Dunckley E., Connor D.J., Sabbagh M.N., Hentz J.G., Noble B., Evidente V.G., Shill H.A., Adler C.H. Defining mild cognitive impairment in Parkinson's disease. Mov. Disord 2007, 22:1272-1277.
11. de Lau L.M., Schipper C.M., Hofman A., Koudstaal P.J., Breteler M.M. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch. Neurol 2005, 62:1265-1269.
12. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., Broe G.A., Cummings J., Dickson D.W., Gauthier S., Goldman J., Goetz C., Korczyn A., Lees A., Levy R., Litvan I., McKeith I., Olanow W., Poewe W., Quinn N., Sampaio C., Tolosa E., Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord 2007, 22:1689-1707.
13. George S., Mufson E.J., Leurgans S., Shah R.C., Ferrari C., Detoledo-Morrell L. MRI-based volumetric measurement of the substantia innominata in amnestic MCI and mild AD. Neurobiol. Aging 2009, 10.1016/j.neurobiolaging.2009.11.006.
14. Grothe M., Zaborszky L., Atienza M., Gil-Neciga E., Rodriguez-Romero R., Teipel S.J., Amunts K., Suarez-Gonzalez A., Cantero J.L. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cereb. Cortex 2010, 20:1685-1695.
15. Hanyu H., Asano T., Sakurai H., Tanaka Y., Takasaki M., Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am. J. Neuroradiol 2002, 23:27-32.
16. Hilker R., Thomas A.V., Klein J.C., Weisenbach S., Kalbe E., Burghaus L., Jacobs A.H., Herholz K., Heiss W.D. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005, 65:1716-1722.
17. Hobson P., Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov. Disord 2004, 19:1043-1049.
18. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
19. Jacobs D.H., Shuren J., Bowers D., Heilman K.M. Anomia in a Patient with a Basal Forebrain Lesion. Cogn. Behav. Neurol 1995, 8:200-207.
20. Janvin C.C., Larsen J.P., Aarsland D., Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov. Disord 2006, 21:1343-1349.
21. Kang Y., Na D.L. Seoul Neuropsychological Screening Battery 2003, Human Consulting Co, Incheon.
22. Kim H., Na D.L. Normative data on the Korean version of the Boston Naming Test. J. Clin. Exp. Neuropsychol 1999, 21:127-133.
23. Lee J.E., Park H.J., Park B., Song S.K., Sohn Y.H., Lee J.D., Lee P.H. A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson's disease dementia and dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 2010, 81:320-326.
24. Levy G., Schupf N., Tang M.X., Cote L.J., Louis E.D., Mejia H., Stern Y., Marder K. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann. Neurol 2002, 51:722-729.
25. Mamikonyan E., Moberg P.J., Siderowf A., Duda J.E., Have T.T., Hurtig H.I., Stern M.B., Weintraub D. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat. Disord 2009, 15:226-231.
26. Mattila P.M., Roytta M., Lonnberg P., Marjamaki P., Helenius H., Rinne J.O. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol 2001, 102:160-166.
27. Muth K., Schonmeyer R., Matura S., Haenschel C., Schroder J., Pantel J. Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region. Biol. Psychiatry 2010, 67:588-591.
28. Niewiadomska G., Baksalerska-Pazera M., Riedel G. The septo-hippocampal system, learning and recovery of function. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:791-805.
29. Oikawa H., Sasaki M., Ehara S., Abe T. Substantia innominata: MR findings in Parkinson's disease. Neuroradiology 2004, 46:817-821.
30. Perry E.K., Curtis M., Dick D.J., Candy J.M., Atack J.R., Bloxham C.A., Blessed G., Fairbairn A., Tomlinson B.E., Perry R.H. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1985, 48:413-421.
31. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol 1999, 56:303-308.
32. Rorden C., Brett M. Stereotaxic display of brain lesions. Behav. Neurol 2000, 12:191-200.
33. Ruberg M., Rieger F., Villageois A., Bonnet A.M., Agid Y. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res 1986, 362:83-91.
34. Shimada H., Hirano S., Shinotoh H., Aotsuka A., Sato K., Tanaka N., Ota T., Asahina M., Fukushi K., Kuwabara S., Hattori T., Suhara T., Irie T. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009, 73:273-278.